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Epigenetic modulators Histone deacetylases (HDACs) and Lysine demethylase (LSD1) are validated tar-
gets for anticancer therapy. Both HDAC1/2 and LSD1 are found in association with the repressor protein
CoREST in a transcriptional co-repressor complex, which is responsible for gene silencing. Combined
modulation of both targets results in a synergistic antiproliferative activity. In the present investigation,
we report about the design and synthesis of a series of polyamine-based HDACs-LSD1 dual binding inhi-
bitors obtained by coupling Vorinostat and Tranylcypromine. Compound 4 emerged as the most promis-
ing of the synthesized series, showing good inhibitory activity towards HDAC1 and LSD1 either in vitro
and in cell-based assay (Ki = 42.52 ± 8.94 nM and IC50 = 3.85 lM, respectively). Furthermore, at 70.0
mM compound 4 induced a more pronounced cytotoxic effect than Vorinostat (68.6% vs 56.6% of dead
cells) in MCF7 cancer cell line.
 2018 Elsevier Ltd. All rights reserved.Cancer is a multifactorial disease whose onset derives from
both genetic and epigenetic events; in recent years, epigenetic
has gained notable consideration and epigenetic targets have been
validated in therapy.1 Epigenetic changes are reversible chromatin
modifications that lead to activation or suppression of gene expres-
sions. The epigenetic control of gene expressions takes place
through modification of the DNA itself, i.e. methylation, or DNA-
associated proteins, i.e. methylation and acetylation. According to
the subject and the type of modification, chromatin can adopt con-
formational changes that lead to the activation or suppression of
gene expression.2 Histone deacetylases (HDACs) are one of the
most important classes of epigenetic enzymes responsible for
removing acetyl groups from histone tails, determining a more
closed, transcriptionally repressed, chromatin structure.3 Abnor-
mal HDACs activity has been found to be associated with the aber-
rant gene expression and the development of several kinds of
cancer.4 Inhibition of HDACs activities restore normal gene expres-
sion resulting in cell cycle arrest, apoptotic cell death and cell dif-
ferentiation.5 Different HDAC inhibitors (HDACis) have been
approved by the FDA, i.e. vorinostat, romidepsin, panobinostat
and belinostat, and chidamide in China, and many others arecurrently under evaluation in clinical trials (Fig. 1).6 Over the years,
several different classes of HDACis have been identified;7 among
them hydroxamate-based compounds hold a special interest in
spite of their unfavourable ADMET properties.8 Hydroxamate-
based inhibitors, among the most potent but rather unselective
HDACis, bear the hydroxamic acid group able to strongly coordi-
nate the Zn2+ located in the active site of the enzyme. The general
structure for hydroxamate-HDACis comprises three main motifs: a
Zn2+ binding group, a hydrophobic spacer and a cap group able to
interact with the surface of the enzyme. Several clinical evidences
reported that HDACis might be more effective as antiproliferative
agents when used in combination with other chemotherapeutic
or epigenetic drugs. For instance, HDACis potentiate the antiprolif-
erative activities of Topoisomerase I and II inhibitors;9,10 further,
HDACis in combination with the EGFR inhibitor Gefitinib synergis-
tically induce growth inhibition and apoptosis induction in
gefitinib-resistant cancer cell lines.11,12 Recently, Bhalla and
coworkers reported that combined inhibition of HDACs and Lysine
demethylase LSD1 is lethal in human AML cells.13 Furthermore, the
same combination resulted in a synergistic increase of apoptotic
cell death in glioblastoma multiforme cell line.14 LSD1 is a histone
demethylase, member of the greater amine oxidase superfamily,
that is responsible, among other activities, for the specific
demethylation of mono- and dimethylated histone H3-Lys4.15
Fig. 1. Structures of known HDACis, Vorinostat, Romidepsin, Panobinostat, Beli-
nostat and Chidamide, and LSD1 inhibitors, Tranylcypromine, 1 and 2.
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scription factors, regulating the expression of a vast array of
genes.16 LSD1 is found in association with the repressor protein
CoREST and HDAC1/2, in a transcriptional co-repressor complex
that is responsible for gene silencing.17 Most of the known LSD1
inhibitors developed share structural features with monoamine
oxidase inhibitors. In particular, Tranylcypromine is a known irre-
versible LSD1 inhibitor and several Tranylcypromine-based deriva-
tives have been reported so far (Fig. 1). The synergistic activity
obtained combining HDACs and LSD1 inhibitors together with
the finding that LSD1 is associated with CoREST and HDAC1/2 pro-
vided the rational for designing dual binding agents able to simul-
taneously modulate HDACs and LSD1. Herein, we report the design,
the synthesis and the preliminary biological evaluation of a series
of polyamine-based HDAC/LSD1 dual binding inhibitors.
The design of these new compounds began with the observation
that various substituents may be introduced at the para position of
the aromatic ring of both Vorinostat and Tranylcypromine without
a dramatic drop in the inhibitory activity. The two pharma-
cophores have been linked through a polyamine chain since it
has been previously demonstrated that a) protonated nitrogen
atoms can establish interactions with negatively charged amino
acids18,19 and b) polyamines interact with both HDACs and LSD1
proteins.20–22 Three different polyamine chains have been chosen
differing in the number of the nitrogen atoms and in the distance
between them; indeed, compound 3 has a spermidine-like linker
(3-3), compound 4 has a spermine linker (3-4-3) and compound
5 carries a spermine-like connecting unit characterized by longer
(6-8-6) polymethylenes chain between the nitrogen atoms (Fig. 2).H
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Fig. 2. Drug design leading to dual binding agents 3–5.During the drafting of this manuscript, two papers reporting
about novel dual HDAC-LSD1 inhibitors appeared.23,24 However,
these compounds turned out to be structurally slightly different
than those reported in the present manuscript.
For the synthesis of target compounds 3–5 a stepwise linear
synthetic approach was developed (Scheme 1). Suberic anhydride
7 was condensed with methyl 4-aminobenzoate 6 to generate
the corresponding acid 8. This was coupled to O-(Tetrahydro-2H-
pyran-2-yl)hydroxylamine in order to obtain the protected
hydroxamic acid 9, using EDC as coupling agent. Basic hydrolysis
of the methyl ester of 9 furnished the carboxylic acid 10 that
was coupled with the suitable protected polyamines 11–13.25,26
Many efforts were carried out in order to optimize the coupling
conditions of 10 with 11–13: after variation of solvents (DCM,
DMF, THF), reaction times and coupling auxiliary (EtOCOCl and
Et3N, IBCF and Et3N, DCC and HOBt, DCC and DMAP, EDC and HOBt)
it was found that the use of EDC and DMAP gave the best yields.
Basic deprotection of the trifluoromethyl protecting group led to
the primary amines 17–19, which further reacted with succinic
anhydride leading to the corresponding acids 20–22. Coupling of
the latter with Boc-protected tranylcypromine27 generated the
fully-protected dimers 24–26. Also in this case, several reaction
conditions were evaluated with the aim to optimize the coupling
reaction and again better yields were obtained using EDC as cou-
pling agent. Final acidic hydrolysis of the Boc-protecting groups
gave the target compounds 3–5 as hydrochloride salts.
As summarized in Table 1, the target compounds 3–5 as well as
the reference compounds Vorinostat and Tranylcypromine were
profiled for their HDAC1-CoREST3 and LSD1-CoREST3 inhibitory
activities in vitro. Unfortunately, compound 5 was endowed with
poor solubility in the media and, therefore, could not be evaluated.
Compounds 3 and 4 retain the activity of the parent compounds
being both active in the nanomolar and in the micromolar range
of concentrations against HDAC1 and LSD1, respectively. However,
by a closer look to the HDAC1 inhibitory activity, it appears that
introduction of a polyamine chain and a second pharmacophore
in the para position of the aromatic ring induces a slightly decrease
in the activity compared to Vorinostat. Indeed, compounds 3 and 4
are respectively 9 and 14- fold less active than Vorinostat (3: Ki =
26.87 ± 7.87 nM; 4: Ki = 42.52 ± 8.94 nM; Vorinostat: Ki = 3.04 ±
0.6 nM). An opposite trend was observed considering the inhibi-
tory activity towards LSD1; in this case, the introduction of the
polyamine chain and a second pharmacophore has a positive effect
on the inhibitory activity with compounds 3 and 4 being respec-
tively 37 and 23-fold more active than Tranylcypromine (3: IC50
= 2.40 lM; 4: IC50 = 3.85 lM; Tranylcypromine: IC50 = 89.08 lM).
Compounds 3 and 4 were then evaluated in cell-based assay.
First, compounds 3 and 4, together with Vorinostat and Tranyl-
cypromine, were evaluated for their cytotoxic activity in MCF7
breast cancer cell line. Vorinostat induced a dose-dependent
decrease in cell viability with an IC50 of 38.2 mM (data not shown).
Higher concentrations of Tranylcypromine were necessary to
decrease MCF-7 viability and the concentration required to reach
the IC50 value was 2518.9 mM (data not shown).
Compounds 3 and 4 significantly decreased MCF-7 viability
starting from the lowest tested concentration and in a dose-depen-
dent manner. The concentration required to reach the IC50 value
was 60.2 lM for compound 3 and 39.6 lM for compound 4
(Fig. 3). The cytotoxic activity of compound 4 was similar to that
of Vorinostat: at 4.0 mM, Vorinostat and compound 4 induced
20.8% and 16.3% decrease in cell viability, respectively, compared
to control cells. Increasing treatment concentrations showed an
analogue trend. A 49.3% and 52.7% decrease in cell viability was
recorded after 24 h incubation with either Vorinostat or compound
4 at 16.0 mM and 35.0 mM, respectively. At the highest concentra-
tion tested (70.0 mM), 4 induced a more pronounced cytotoxic
Scheme 1. i) THF, rt, 12 h; ii) NH2OTHP, EDC, DMAP, Et3N, DCM, rt, 12 h; iii) NaOH, MeOH, 50 C, 2 h; iv) 11–13, EDC, HOBt, Et3N, THF, rt, 16 h; v) NaOH, MeOH, rt, 16 h; vi)
succinic anhydride, Et3N, DCM, rt, 16 h; vii) 23, EDC, DMAP, DCM, rt, 24 h; viii) HCl 4 M/dioxane, DCM rt, 12 h.
Table 1
HDAC1-CoREST3 and LSD1-COREST3 inhibiting activity of the dual binding agents 3–5
in comparison with Vorinostat and Tranylcypromine.
Compounda HDAC1-CoREST3
Ki (nM)
LSD1-CoREST3
IC50 (lM)
3 26.87 ± 7.87 2.40
4 42.52 ± 8.94 3.85
5 n.d. n.d.
Vorinostat 3.04 ± 0.6 n.d.
Tranylcypromine n.d. 89.08
n.d. = not determined.
a Compounds as hydrochloride salts.
Fig. 3. Cell viability after 24 h treatment of MCF-7 cells with a) compound 3, b)
compound 4 and c) compounds 3 and 4 in comparison with Vorinostat.
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Compound 3 exhibited a lower cytotoxic activity with only 52%
decrease in cell viability recorded at the highest concentration
tested (Fig. 3). Tranylcypromine showed cytotoxic effects at con-
centrations much higher than the other compounds (data not
shown).
To explore the ability of compounds 3 and 4 to inhibit HDACs in
cell, nuclear extracts of treated MCF-7 cells were compared to Vori-
nostat plus Tranylcypromine-treated cells. Based on the results of
the preliminary evaluation that allowed to define the cytotoxic
activity, cells were treated with concentrations similar or lower
than the IC50: 70.0 mM for compound 3, 17.0 mM for compound 4,
Fig. 4. Relative HDAC activity of Vorinostat (35 lM) plus Tranylcypromine (1000
lM), compounds 3 (70 lM) and 4 (17 lM) on MCF-7 nuclear extracts.
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The HDAC activity levels of all tested compounds were significantly
lower than the HDAC activity levels of untreated samples (Fig. 4). A
HDAC enzyme inhibition of 50.2% was recorded after treatment
with 17.0 mM of compound 4 (Fig. 4). The inhibitory activity of
compound 4 was similar to that induced by the combination of
Vorinostat plus Tranylcypromine (50.0%). As expected from the
cytotoxic results, compound 3 had the lowest rate of HDAC inhibi-
tion: after 70.0 mM treatment, the reduction of enzyme activity was
35.8% (Fig. 4).
Designing dual binding agents is a well established strategy in
medicinal chemistry to provide new drug candidates or biochemi-
cal tools. In the present investigation, we explored the structure-
activity relationships data available for HDAC and LSD1 inhibitors
to design the first class of polyamine-based dual HDAC/LSD1 inhi-
bitors. Indeed, it is well known that HDAC1/2 and LSD1 are associ-
ated within the same complex with CoREST. These new dual
binding agents were obtained by linking the structure of two
well-known HDAC and LSD1 inhibitors, namely Vorinostat and
Tranylcypromine. As linker different polyamine chains have been
choose. Indeed, polyamines are known to establish additional
interaction with negative charged amino acids. The obtained com-
pounds showed in vitro activity towards HDAC1 and LSD1 compa-
rable to that exhibited by the parent compounds Vorinostat and
Tranylcypromine as well as in cell HDAC inhibition comparable
to that induced by a combination of Vorinostat and
Tranylcypromine.
Furthermore, compounds 3 and 4 possess cytotoxic activity in
the micromolar range of concentration in MCF7 breast cancer line.
Therefore, this report provides the first polyamine-based com-
pounds that allowed the simultaneous modulation of HDAC and
LSD1 with a single molecule. Deeper biological investigations, i.e.
antiproliferative effects on other cancer cell lines, analysis of the
mechanisms of cell death etc., as well as synthesis of other ana-
logues are currently pursued in our laboratories and will be
reported in due course.Acknowledgments
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